Increased Soluble CD155 in the Serum of Cancer Patients

Emerging evidence suggests that DNAM-1 (CD226) play an important role in the recognition of tumor cells and their lysis by cytotoxic T lymphocytes (CTL) and NK cells. Although the DNAM-1 ligand CD155 is ubiquitously expressed in various tissues, many human tumors significantly upregulate the express...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2016-04, Vol.11 (4), p.e0152982-e0152982
Main Authors: Iguchi-Manaka, Akiko, Okumura, Genki, Kojima, Hiroshi, Cho, Yukiko, Hirochika, Rei, Bando, Hiroko, Sato, Toyomi, Yoshikawa, Hiroyuki, Hara, Hisato, Shibuya, Akira, Shibuya, Kazuko
Format: Article
Language:English
Subjects:
Aged
Animal tissues
Animals
Bioindicators
Biology and Life Sciences
Biomarkers
Biomarkers, Tumor - blood
Cancer
Cancer patients
Care and treatment
Case-Control Studies
CD226 antigen
Cytotoxicity
Gastric cancer
Gene expression
Gynecology
Health aspects
Hospitals
Human tissues
Humans
Immunity
Immunoglobulins
Immunology
Isoforms
Killer Cells, Natural - immunology
Leukemia
Ligands
Lungs
Lymphocytes
Lymphocytes T
Lysis
Medical research
Medicine
Medicine and Health Sciences
Melanoma
Mice
Middle Aged
Natural killer cells
Neoplasms - blood
Neoplasms - pathology
Obstetrics
Patients
Physiological aspects
Proteins
R&D
Receptors, Virus - blood
Research & development
Research and Analysis Methods
Surgery
T cells
T-Lymphocytes, Cytotoxic - immunology
Tumor cells
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Emerging evidence suggests that DNAM-1 (CD226) play an important role in the recognition of tumor cells and their lysis by cytotoxic T lymphocytes (CTL) and NK cells. Although the DNAM-1 ligand CD155 is ubiquitously expressed in various tissues, many human tumors significantly upregulate the expression of CD155; DNAM-1 on CTL and NK cells may be involved in tumor immunity. However, unlike those in mice, human tissues also express soluble isoforms of CD155 (sCD155) that lack the transmembrane region. Here, we show that sCD155 levels were significantly higher in the sera of 262 patients with lung, gastrointestinal, breast, and gynecologic cancers than in sera from healthy donors. In addition, the sCD155 levels were significantly higher in patients with early stage (stages 1 and 2) gastric cancer than in healthy donors, and were significantly higher in patients with advanced stage (stages 3 and 4) disease than in patients in those with early stage disease and healthy donors. Moreover, the sCD155 levels were significantly decreased after surgical resection of cancers. Thus, sCD155 level in serum may be potentially useful as a biomarker for cancer development and progression.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0152982